tbuckley/cabot-search huggingface dataset:
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Authors: Stephanie L. Goff, Mark E. Dudley, Deborah E. Citrin, Robert P. Somerville, John R. Wunderlich, David N. Danforth, Daniel A. Zlott, James C. Yang, Richard M. Sherry, Udai S. Kammula, Christopher A. Klebanoff, Marybeth S. Hughes, Nicholas P. Restifo, Michelle M. Langhan, Thomas E. Shelton, Lily Lu, Mei Li M. Kwong, Sadia Ilyas, Nicholas D. Klemen, Eden C. Payabyab, Kathleen E. Morton, Mary Ann Toomey, Seth M. Steinberg, Donald E. White, Steven A. Rosenberg
Journal: Journal of Clinical Oncology (2016)

Adoptive cell transfer, the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52 of 93; 56%). Addition and intensification of total body irradiation (TBI) to the preparative lymphodepleting chemotherapy regimen in sequential trials improved objective partial and complete response (CR) rates. Here, we evaluated the importance of adding TBI to the adoptive transfer of tumor-infiltrating lymphocytes (TIL) in a randomized fashion.A total of 101 patients with metastatic melanoma, including 76 patients with M1c disease, were randomly assigned to receive nonmyeloablative chemotherapy with or without 1,200 cGy TBI before transfer of tumor-infiltrating lymphcytes. Primary end points were CR rate (as defined by Response Evaluation Criteria in Solid Tumors v1.0) and overall survival (OS). Clinical and laboratory data were analyzed for correlates of response.CR rates were 24% in both groups (12 of 50 v 12 of 51), and OS was also similar (median OS, 38.2 v 36.6 months; hazard ratio, 1.11; 95% CI, 0.65 to 1.91; P = .71). Thrombotic microangiopathy was an adverse event unique to the TBI arm and occurred in 13 of 48 treated patients. With a median potential follow-up of 40.9 months, only one of 24 patients who achieved a CR recurred.Adoptive cell transfer can mediate durable complete regressions in 24% of patients with metastatic melanoma, with median survival > 3 years. Results were similar using chemotherapy preparative regimens with or without addition of TBI.
The relationship between legal status and patient characteristics in state hospitals
Authors: R L Okin
Journal: American Journal of Psychiatry (1986)

Concerns raised in response to proposals that general hospitals admit patients who currently receive acute care in state hospitals have focused primarily on certain assumptions about the characteristics of involuntary patients in contrast to their voluntary counterparts. The author compared a group of voluntary and involuntary patients in seven state hospitals. Contrary to some recent reports, legal status was not associated with chronicity, prevalence of psychosis, extent of social ties as measured by marital status and living situation, or need for seclusion or restraint. The two groups differed significantly in median length of stay but in an opposite direction from that previously reported.
Psychiatric education at the crossroads: issues and future directions
Authors: A Beigel
Journal: American Journal of Psychiatry (1979)

Psychiatric education is currently facing many critical issues. Their resolution will determine the future availability of psychiatrists and is dependent on the development of new strategies that will require a reorientation in several aspects of current psychiatric education. This may be necessary if the vitality of psychiatry as a specialized branch of medicine is to be maintained and the relevance of psychiatric training and practice to service needs and research objectives is to be increased.
Corticosteroid Osteonecrosis
Authors: C T Chin, R C Sarno
Journal: New England Journal of Medicine (1995)

Figure 1. Plain films of the knees of a 50-year-old woman receiving long-term corticosteroid therapy reveal medullary bone infarcts in the distal femurs and proximal tibias. Serpiginous lucencies with peripheral sclerotic rims represent necrotic spongy bone and marrow walled off by calcified collagenous fibrous tissue. Osteonecrosis can also occur with short-term use of corticosteroids.
A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study
Authors: Emanuela Messa, Daniela Maria Gioia, Elisa Masiera, Bernardino Allione, Emanuele Angelucci, Enrico Balleari, Margherita Bonferroni, Gianni Cametti, Riccardo Centurioni, Elena Crisà, Daniela Cilloni, Paolo Danise, Lisette Del Corso, Dario Ferrero, Carlo Finelli, Roberto Freilone, Gianluca Gaidano, Monia Lunghi, Pellegrino Musto, Esther Natalie Oliva, Stefano Pappano, Anna Maria Pelizzari, Antonella Poloni, Valeria Santini, Flavia Salvi, Rodolfo Tassara, Giuseppe Visani, Giuseppe Saglio, Alessandro Levis
Journal: Blood (2013)
μPET imaging of the pharmacokinetic behavior of medium and high molar mass 89 Zr-labeled poly(2-ethyl-2-oxazoline) in comparison to poly(ethylene glycol)
Authors: Leonie wyffels, Thomas Verbrugghen, Bryn D. Monnery, Mathias Glassner, Sigrid Stroobants, Richard Hoogenboom, Steven Staelens
Journal: Journal of Controlled Release (2016)
Screening for Phenylketonuria
Authors: G. M. Komrower
Journal: BMJ (1969)

<h3>Introduction</h3> On recommencement of surveillance after the first wave of the Covid-19 pandemic, the BSG guidelines for colonoscopy surveillance had been updated in October 2020. This created an opportunity to reassess all 1243 colonoscopy surveillance patients by developing a new surveillance nurse led pathway at Wye Valley NHS Trust Hereford (WVT). <h3>Methods</h3> A new Band 7 Non-medical Endoscopist was appointed on transition from Bowel Scope to BCSP and set up a new assessment process to review surveillance patients against the new BSG criteria. Patients who no longer met the new guidelines were written to explaining the change in the BSG criteria. Patients still meeting the surveillance criteria were invited to a nurse led clinic where suitability for colonoscopy was assessed, specific instructions regarding bowel preparation given, renal function assessed and arrangements made for anticoagulation ± diabetic control. Clinics were either face to face or via telephone according to the patient’s wishes. <h3>Results</h3> 1243 patients on the initial colonoscopy surveillance waiting list underwent initial validation and 39% of patients were discharged as they no longer met the surveillance criteria. A further 8% were discharged for other reasons (moved away, new health concerns). After clinic assessment, only 34% of the original surveillance cohort were suitable for surveillance colonoscopy, 3% were not fit enough for any surveillance, 2% declined any colonic investigations, 2% agreed to CTC, 2% DNAd, 1% had moved away and 4% were Covid anxious and requested a delay in surveillance. 5% were upgraded to C2WW due to new symptoms. With a combination of reducing demand and increasing capacity back to pre-Covid levels, surveillance waiting times have reduced from 12 months to 6 weeks. The discharges have released 151 colonoscopy lists (758 colonoscopies) to the C2WW and screening programmes. Using NHS tariff for colonoscopy of £372, these 758 discharges achieved a financial benefit of £281,976. The surveillance clinic cost has been 2 Band 7 nursing clinics per week over an 8 month period annualised to £8960 pa. <h3>Conclusions</h3> Nurse led clinics can thoroughly assess colonoscopy surveillance patients against the new BSG guidelines. This substantially reduces demand, reduces waiting times and generates a cost benefit. Quality is also enhanced by specific information of the procedure and anticoagulation issues. This has reduced surveillance waiting times down to JAG recommendations within 8 months. Our new surveillance process has released a total of 151 colonoscopy lists by demonstrating only 34% of the initial cohort of patients remained suitable for colonoscopy surveillance.
Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus
Authors: Don S. Dizon, Michael J. Birrer
Journal: JNCI Journal of the National Cancer Institute (2015)

For women with early-stage ovarian or endometrial cancers, prognosis is very good, with overall survival for both sites between 80% and 90%. This stands in stark contrast to metastatic disease (advanced stage), where the overall survival is less than 15%. We have long recognized that subtypes of disease also inform these statistics, with high-grade serous carcinomas conferring a far worse prognosis compared with others, including low-grade serous or endometrioid tumors. Yet even with our present understanding, a not uncommon finding is the diagnosis of women with carcinoma at both the ovary and the uterus (a situation that occurs in up to 10% of patients), raising the question of synchronous primaries or of metastatic disease. The implications of these clinical senarios are very relevant: If a conclusion of synchronous primaries is made, then prognosis should be excellent and hence no further treatment beyond surgery is required for cure. However, the finding of metastatic disease (from the ovary to the uterus or vice versa) will substantially change the prognostic implications, with these patients having a higher risk of recurrence and death from metastatic disease. In addition, this differential diagnosis can change therapeutic recommendations, with metastatic disease requiring more aggressive adjuvant therapy. Thus, the issue is both a biologic and clinical one.
A Digital Health Intervention to Lower Cardiovascular Risk
Authors: Sonia S. Anand, Zainab Samaan, Catherine Middleton, Jane Irvine, Dipika Desai, Karleen M. Schulze, Stena Sothiratnam, Fathima Hussain, Baiju R. Shah, Guillaume Pare, Joseph Beyene, Scott A. Lear
Journal: JAMA Cardiology (2016)

<h3>Importance</h3> South Asian individuals have a high burden of premature myocardial infarction (MI). <h3>Objectives</h3> To test whether a digital health intervention (DHI) designed to change diet and physical activity improves MI risk among a South Asian population. <h3>Design, Setting, and Participants</h3> This single-blind, community-based, randomized clinical trial with 1-year follow-up was performed among South Asian men and women 30 years or older and living in Ontario and British Columbia who were free of cardiovascular disease. Data analysis was by intention to treat. Data were collected from June 3, 2012, to October 27, 2013. Final follow-up was completed on December 2, 2014, and data were analyzed from April 2, 2015, to February 29, 2016. <h3>Interventions</h3> Participants were randomized 1:1 to the DHI or control condition. The goal-setting DHI used emails or text messages and focused on improving diet and physical activity that was tailored to the participant's self-reported stage of change. <h3>Main Outcomes and Measures</h3> The change in an MI risk score from baseline to 1 year was the primary outcome. Secondary outcomes included the change in each objectively measured component of the MI risk score (ie, blood pressure, waist to hip ratio, hemoglobin A<sub>1c</sub>level, and the ratio of apolipoprotein B to apolipoprotein A). Genetic risk for MI was determined by counting the 9p21 risk alleles; results were provided to each participant at baseline. <h3>Results</h3> A total of 343 South Asian men and women (178 men [51.9%]; mean [SD] age, 50.6 [11.4] years) who were free of cardiovascular disease were randomized to the control condition (n = 174) or the DHI (n = 169). The mean (SD) MI risk score was 13.3 (6.6) at baseline. No significant difference was found in the change in MI score after 1 year between the DHI and control groups (−0.27; 95% CI, −1.12 to 0.58;<i>P</i> = .53) after adjusting for baseline scores, and no difference was found in the fully adjusted model (−0.39; 95% CI, −1.24 to 0.45;<i>P</i> = .36). No association between knowledge of the genetic risk status at baseline and the change in MI risk score was found (0.19; 95% CI, −0.40 to 0.78;<i>P</i> = .53). <h3>Conclusions and Relevance</h3> Among South Asian individuals, a DHI was not associated with a reduction in MI risk score after 12 months and was not influenced by knowledge of genetic risk status. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01841398
An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms
Authors: J L Waddington, H A Youssef
Journal: American Journal of Psychiatry (1986)

Factors associated with the emergence or nonemergence of involuntary movements (tardive dyskinesia) during long-term neuroleptic treatment were investigated in an atypical, isolated population of 31 schizophrenic inpatients with an unusually high prevalence of this syndrome. Patients with involuntary movements could not be distinguished from those without such movements by general characteristics or conventional indices of neuroleptic or anticholinergic treatment. However, they were more likely to show either marked cognitive dysfunction or muteness. These findings support the proposal that, at least in schizophrenia, subtle organic changes may contribute to vulnerability to the emergence of involuntary movements.
Individual Patterns of Urinary 17-Ketosteroid Fractions
Authors: W M JEFFERIES, A M MICHELAKIS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P0941 : CD44 is an important actor in non alcoholic steatohepatitis
Authors: D. Rousseau, R. Anty, S. Bonnafous, S. Patouraux, A.-S. Schneck, A. Iannelli, M.-C. Saint-Paul, J. Gugenheim, B. Bailly-Maitre, A. Tran, P. Gual
Journal: Journal of Hepatology (2015)
Pay drug companies $1bn for each new antibiotic, says report
Authors: Jonathan Owen
Journal: BMJ (2016)

Pharmaceutical companies should be given rewards of more than one billion dollars for each new antibiotic they bring to the market, according to the final report of an independent review on antimicrobial resistance.1

Around $40bn (£28bn; €35bn) needed to be spent during the next decade to fight “one of the biggest health threats that the world faces,” according to the Tackling Drug-Resistant Infections Globally report, “with huge human and economic costs if we do not address it.”

The report was the result of a review chaired by Jim O’Neill, commercial secretary to the UK Treasury, which was commissioned by Prime Minister David Cameron two years ago and funded by the government and the Wellcome Trust.

Worldwide, about 700 000 people died each year from drug resistant strains of bacterial infections, tuberculosis, malaria, and …
Comparison of measures used to determine substance abuse in an inpatient psychiatric population
Authors: M J Albanese, R L Bartel, R F Bruno, M W Morgenbesser, A F Schatzberg
Journal: American Journal of Psychiatry (1994)

Eighty-nine of 178 consecutively admitted inpatients were administered the substance abuse sections of the Structured Clinical Interview for DSM-III-R--Patient Version (SCID-P). Patients also provided a urine sample for toxicologic analysis. In addition, primary clinicians assigned admission and discharge diagnoses. Test characteristics (e.g., sensitivity) for confirming a current diagnosis of psychoactive substance abuse were calculated for each measure and compared. Urine toxicology analyses and admission and discharge diagnoses were significantly less accurate in diagnosing psychoactive substance abuse than the SCID-P. This finding indicates that substance abuse is frequently not noted during routine admission and discharge assessments.
Abstract B2-34: Model guided understanding of synergistic combination therapies in the DNA damage response pathway
Authors: Andreas Raue, Ozan Alkan, Daryl Drummond, Birgit Schoeberl
Journal: Cancer Research (2015)

Abstract Most commonly used anti-cancer therapies involve the systemic administration of anti-proliferative and DNA damaging agents. Deregulation of DNA damage response (DDR) pathways can cause resistance to DNA damaging therapies. Synergistic combination strategies of novel DDR pathway modulators promise to re-sensitize to and amplify currently used standard-of-care therapies. Our goal is to gain mechanistic understanding of the DDR pathway by developing a predictive computational model using single cell microscopy phenotypic data and signaling data from a panel of cancer cell lines. We focus on synergistic and potentiating effects of drug combinations using standard-of-care drugs such as doxorubicin, gemcitabine and irinotecan, and DDR pathway modulators. Our computational model explains the mechanisms of synergistic or additive phenotype that are observed for various modulators and was validated using DDR signaling data. The presented computational model rationalizes the design of novel combination therapies targeting the DDR pathway, includes heterogeneity of different cell lines and is an important step towards the design of a biomarker strategy. Citation Format: Andreas Raue, Ozan Alkan, Daryl Drummond, Birgit Schoeberl. Model guided understanding of synergistic combination therapies in the DNA damage response pathway. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr B2-34.
Diphtheria Carriers
Authors: LOUIS W. MILLER
Journal: Annals of Internal Medicine (1975)

Comments and Correction1 May 1975Diphtheria CarriersLOUIS W. MILLER, M.D.LOUIS W. MILLER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-82-5-720_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: McCloskey and colleagues reported in the December 1974 issue (Ann Intern Med 81:788-791, 1974) their experience in the treatment of a large number of Corynebacterium diphtheriae carriers. Although I agree with the need to treat carriers and the recommendation that erythromycin be the preferred antibiotic, I feel it is important to mention several problems related to the C. diphtheriae carrier state and the evaluation of its treatment.McCloskey and associates stated that treatment of diphtheria carriers is superior to no treatment because one Russian report showed that only 12% of carriers becomeC. diphtheriae-negative when followed for...References1. WEAVER G: Diphtheria carriers. JAMA 76:831-835, 1921 CrossrefGoogle Scholar2. MILLERBICKHAMJONES LSW: Diphtheria carriers and the effect of erythromycin therapy. Antimicrob Agents Chemother 6:166-169, 1974 CrossrefMedlineGoogle Scholar3. DOULLLARA JH: The epidemiologic importance of diphtheria carriers. Am J Hyg 5:508-529, 1925 Google Scholar4. MILLEROLDERDRAK LJJ: Diphtheria immunization: effect upon carriers and the control of outbreaks. Am J Dis Child 123:197-199, 1972 CrossrefMedlineGoogle Scholar1. MCCLOSKEYSARAGEAMAXIMESCU RAP: Phage typing in diphtheria outbreak in the Southwest 1970-71. J Infect Dis 126: 196-199, 1972 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Social and Preventive Medicine University of Maryland School of Medicine Baltimore, Maryland 21201 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1975Volume 82, Issue 5Page: 720-720KeywordsAntibioticsDiphtheriaErythromycin Issue Published: 1 May 1975 PDF DownloadLoading ...
Clarification of entry criteria for the European Organization for Research and Treatment of Cancer H5-favorable trial of early-stage Hodgkin's disease.
Authors: G M Rasp, M G Haddock, J A Martenson
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.8.1739 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8080569 Clarification of entry criteria for the European Organization for Research and Treatment of Cancer H5-favorable trial of early-stage Hodgkin's disease. G M RaspxG M RaspSearch for articles by this author , M G HaddockxM G HaddockSearch for articles by this author , J A MartensonxJ A MartensonSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.8.1739 PDF "Clarification of entry criteria for the European Organization for Research and Treatment of Cancer H5-favorable trial of early-stage Hodgkin's disease.." Journal of Clinical Oncology, 12(8), pp. 1739–1740© 1994 by American Society of Clinical Oncology
Bilateral Mammary Cancer in Italian Women
Authors: P MUSTACCHI, A PANDOLFI, P BUCALOSSI
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Bilateral Mammary Cancer in Italian Women Get access Piero Mustacchi, Piero Mustacchi Biometry Branch, National Cancer Institute,5Bethesda, Maryland, and Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Anna Pandolfi, Anna Pandolfi Biometry Branch, National Cancer Institute,5Bethesda, Maryland, and Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Pietro Bucalossi Pietro Bucalossi Biometry Branch, National Cancer Institute,5Bethesda, Maryland, and Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 6, December 1957, Pages 1035–1042, https://doi.org/10.1093/jnci/19.6.1035 Published: 01 December 1957 Article history Received: 20 May 1957 Published: 01 December 1957
Case 47-1963
Authors: Allan I. Sandler, Robert E. Scully
Journal: New England Journal of Medicine (1963)

Presentation of CaseA seventy-two-year-old widow was admitted to the hospital because of diarrhea.The patient had had occasional episodes of flatulence and eructation for several years. Eighteen months before entry she consulted a physician because of crampy pain in the lower portion of the abdomen and increasing flatulence and was told that she had diverticulitis. The symptoms improved spontaneously over the next few months. Eight months before admission she lost her appetite and began to pass 15 to 30 watery, yellow, occasionally lumpy stools daily; the feces were not unusually malodorous. She also complained of the expulsion of large . . .
Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Authors: Ajay K. Nooka, Jonathan L. Kaufman, Madhusmita Behera, Charise Gleason, Hannah Collins, Vikas A. Gupta, Lawrence H Boise, Sagar Lonial
Journal: Blood (2015)